Ignite Creation Date:
2025-12-24 @ 6:33 PM
Ignite Modification Date:
2026-03-08 @ 12:25 AM
Study NCT ID:
NCT00506857
Status:
COMPLETED
Last Update Posted:
2012-02-28
First Post:
2007-07-23
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Hematologic Malignancies | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Hematologic Malignancies | View |
| None | Blood And Marrow Transplantation | View |
| None | Leukemia | View |
| None | MDS | View |
| None | Lymphoma | View |
| None | Myeloma | View |
| None | Fludarabine | View |
| None | Fludara | View |
| None | Fludarabine Phosphate | View |
| None | Busulfan | View |
| None | Busulfex | View |
| None | Myleran | View |
| None | Progenitor Cell Transplantation | View |
| None | Granulocyte colony stimulating factor | View |
| None | G-CSF | View |
| None | Apheresis | View |
| None | Blood cell infusion | View |